Abiopharma

(99% Neutral) Imago BioSciences, Inc. (IMGO) Files Form 8-K

(70% Positive) MIRATI THERAPEUTICS, INC. (MRTX) Announces Clinical Development Update

(80% Positive) Global Blood Therapeutics, Inc. (GBT) Announces Enrollment Update for options Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

(99% Neutral) Molecular Templates, Inc. (MTEM) Announces Regulatory Update

(90% Positive) Verastem, Inc. (VSTM) Files Form 8-K

(99% Neutral) PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Clinical Development Update

(90% Positive) RADIUS HEALTH, INC. (RDUS) Files Form 8-K

(85% Positive) Arbutus Biopharma Corporation (ABUS) Provides Update on patients for a Phase 2a clinical trial

(10% Negative) AstraZeneca (AZN) Announces Clinical Development Update (Form 6-K)

(10% Negative) Intercept Pharmaceuticals, Inc. (ICPT) Announces Delay in trial Trials for liver fibrosis due to NASH Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment